ROBERT CAULKINS: Open Payments
NPI 1992744031 · BREMERTON, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,733 in 77 payments from 23 companies in 2025. Trend: 2023 $2,006 · 2024 $2,293 · 2025 $1,733
Food & beverage: $1,733
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $199 |
| GlaxoSmithKline, LLC. | 8 | $194 |
| ABBVIE INC. | 14 | $194 |
| Lilly USA, LLC | 7 | $167 |
| Amgen Inc. | 5 | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $135 |
| Novo Nordisk Inc | 5 | $112 |
| PFIZER INC. | 4 | $90 |
| Lundbeck LLC | 4 | $88 |
| Teva Pharmaceuticals USA, Inc. | 2 | $70 |
Products named: VRAYLAR, JARDIANCE, MOUNJARO, TRELEGY ELLIPTA, REXULTI, BREZTRI, AUSTEDO XR, FARXIGA.
Industry payments across WA — which companies pay providers there.
